Beroni Group Ltd Ordinary Shares Stock (OTC: BNIGD)

Latest news for Beroni Group Ltd Ordinary Shares (OTC:BNIGD) Stock

Beroni Group Ltd Ordinary Shares

News

Analyst Ratings

Trading Ideas

Live On CNBC, Jenny Harrington Announces Sold 3M Company

Bernstein analyst Callum Elliott maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Market Perform and raises the price target from $100 to $103.

Price Target

Bernstein Maintains Market Perform on Colgate-Palmolive, Raises Price Target to $103

Rosenblatt analyst Hans Mosesmann maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and maintains $85 price target.

LSCC

Rosenblatt Maintains Buy on Lattice Semiconductor, Maintains $85 Price Target

Rosenblatt analyst Kevin Cassidy maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Neutral and raises the price target from $70 to $75.

Rosenblatt Maintains Neutral on ON Semiconductor, Raises Price Target to $75

BMO Capital analyst Brian Pitz reiterates Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Outperform and maintains $92 price target.

Reiteration

UBER

BMO Capital Reiterates Outperform on Uber Technologies, Maintains $92 Price Target

Artificial intelligence progress and advertising spending are among the topics analysts and investors are eyeing when Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) reports second-quarter financial results <a href="https://www.benzinga.com/earnings">after market close Wednesday, July 31.</a>
Earnings Estimates: Analysts estimate Meta Platforms will report second-quarter revenue of $38.3 billion according to data <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent073024&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company reported revenue of $32.0 billion in last year's second quarter. Meta Platforms has beaten analysts' revenue estimates in seven straight quarter sand eight of the last 10 quarters.
Analysts estimate Meta will report second-quarter earnings per share of $4.73, compared to $2.98 reported in last year's second quarter. The company beat analysts' estimates for earnings per share in five straight quarters and six of the last 10 quarters.
<a href="https://www.benzinga.com/news/earnings/24/04/38416273/meta-platforms-q1-earnings-highlights-facebook-owner-beats-estimates-but-guidance-higher-costs-ding">Guidance from </a>Meta Platforms calls for revenue to be in a range of $36.5 billion to $39 billion.
Read Also: <a href="https://www.benzinga.com/news/24/07/40027527/mark-zuckerberg-gets-triggered-by-closed-ai-models-at-siggraph-2024-drops-f-bomb-while-talking-with">Mark Zuckerberg Drops F-Bomb While Talking With Nvidia CEO: &#8216;There Goes Our Broadcast Opportunity&#8217;</a>
What Analysts Are Saying: Investor sentiment for Meta is mixed, RBC Capital analyst Brad Erickson writes.
The analyst, who has an Outperform rating and $570 price target said the risk/reward on Meta stock is slightly favorable.
"Sentiment has been a whipsaw over the past month where we're finding more now leaning positive near term at current levels while still maintaining relative skepticism beyond the quarter," Erickson said.
Erickson said small business marketing checks show constructive advertising spending trends for the second and third quarters.
"We believe that despite a somewhat marginally softer consumer combined with evidence of worsening KPIs, advertisers continue to spend on the best digital channels which includes META."
The analyst said Meta's ad platform and new AI tools are performing well. This could lead to increased capture rates and advertising revenue.
Outside of advertising, Erickson said Meta's artificial intelligence strategy is a key from the earnings report.
"The Street will be looking for more on the bigger picture AI monetization strategy where last quarter's performance by management was more challenging."
Here are other recent<a href="https://www.benzinga.com/quote/META/analyst-ratings"> analyst ratings for Meta Platforms</a> and their price targets:
<ul>
<li>Needham: Reiterated Underperform rating, no price target</li>
<li>Benchmark: Reiterated Hold rating, no price target</li>
<li>Wedbush: Reiterated Outperform rating, $570 price target</li>
<li>Bernstein: Maintained Outperform rating, raised price target from $565 to $575</li>
<li>Oppenheimer: Maintained Outperform, raised price target from $500 to $525</li>
<li>Wolfe Research: Initiated with Outperform rating, $620 price target</li>
<li>TD Cowen: Maintained Buy rating, raised price target from $530 to $600</li>
<li>Wells Fargo: Maintained Overweight rating, raised price target from $593 to $625</li>
</ul>
Key Items to Watch: AI will likely be a key item for investors and analysts. Meta CEO Mark Zuckerberg recently unveiled<a href="https://www.benzinga.com/news/24/07/40030481/mark-zuckerberg-announces-metas-ai-studio-roll-out-at-siggraph-2024-now-create-custom-chatbots-for-y"> the rollout </a>of an AI Studio where creators can make custom AI chatbots for social media profiles.
Job cuts and spending could be another topic that could impact the stock price. In the first quarter, Meta raised its guidance for full-year 2024 expected expenses to a range of $96 billion to $99 billion. Higher infrastructure and legal costs were cited as the reason for the change from a range of $94 billion to $99 billion.
Any further raises to expenses could spook some investors away from the stock. Meta walks a cautious line of investing in future growth like its AI roadmap and also not spending too much.
Mentioned above by Erickson, advertising rates are a key for the quarter. Meta reported ad impressions were up 20% year-over-year in the first quarter with the average price per ad up 6% year-over-year. Investors will likely want to see continued momentum and year-over-year increases for both metrics.
META Price Action: Meta Platforms shares trade at $467.50 versus a 52-week trading range of $274.38 to $542.81. Meta stock is up 47% over the last year and up 32% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40028341/senate-set-to-approve-new-child-online-safety-bill-on-tuesday-what-it-means-for-elon-musks-x-meta-sn">Senate Set To Approve New Child Online Safety Bill On Tuesday: What It Means For Elon Musk&#8217;s X, Meta, Snap And TikTok</a></li>
</ul>

Analyst Color

Previews

Meta Platforms Q2 Earnings Preview: AI In Focus As 'Advertisers Spend On The Best Digital Channels — Including Meta,' Analyst Says

Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares are trading lower today. 
The company introduced its Structera line of Compute Express Link (CXL) devices, designed to address memory performance and scaling challenges in general-purpose <a href="https://www.benzinga.com/pressreleases/24/07/n40037355/marvell-introduces-breakthrough-structera-cxl-product-line-to-address-server-memory-bandwidth-and-" target="_blank" rel="noreferrer noopener">servers for cloud data centers</a>.
To tackle memory-intensive applications, data centers often add extra servers to increase memory bandwidth and capacity, which can lead to inefficiencies as additional computing power remains underutilized. The CXL industry-standard solves this by allowing new architectures to efficiently expand the memory of general-purpose servers.
Bob Wheeler, principal analyst at Wheeler&#8217;s Network stated, &#8220;Marvell has developed a long-term vision for CXL that capitalizes on this diversity of uses and will encourage hyperscalers and others to adopt CXL to scale the so-called memory wall.&#8221;
Raghib Hussain, president of products and technologies, said, &#8220;Our new Structera CXL product line will be a game-changer in enabling optimal resource utilization and lowering energy consumption for scaling memory-intensive workloads in the cloud.&#8221;
&#8220;Marvell is delivering on the promise of CXL and our commitment to customers to help them solve their most challenging issues. CXL will continue to be a critical technology enabler for accelerated infrastructure across our compute, connectivity and storage portfolios,&#8221; Hussain added.
&#8220;Marvell is an important CXL ecosystem partner to Micron, and our work together will help advance the adoption of memory expansion in the industry. Our collaboration on memory interoperability will enable flexible and scalable memory resources to match increasing processor core counts and data-intensive workloads,&#8221; said Vijay Nain, senior director of CXL Product Management at Micron. 
This week, Marvell announces the Teralynx 10 Ethernet switch device is in volume production <a target="_blank" href="https://www.benzinga.com/news/24/07/39967397/whats-going-on-with-marvell-stock" rel="noreferrer noopener">with customer deployments underway</a>.
Investors can gain exposure to the stock via Spear Alpha ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRX#NASDAQ">SPRX</a>) and Columbia ETF Trust I Columbia Seligman Semiconductor And Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMI#NYSE">SEMI</a>).
MRVL Price Action: Marvell Technologies shares are down 1.52% at $63.50 at the last check Tuesday.
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/06/39527484/marvells-new-digital-signal-processor-technology-enhances-ai-data-centers" target="_blank" rel="noreferrer noopener">Marvell&#8217;s New Digital Signal Processor Technology Enhances AI Data Centers</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Movers

Tech

MRVL

SEMI

SPRX

What's Going On With Marvell Stock Tuesday?

BMO Capital analyst Brian Pitz reiterates Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Outperform and maintains $185 price target.

TTWO

BMO Capital Reiterates Outperform on Take-Two Interactive, Maintains $185 Price Target

Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) shares are trading higher by 0.64% to $148.40 during Tuesday&#8217;s session. Traders and investors are watching for the company&#8217;s first-quarter earnings report, confirmed for Tuesday&#8217;s <a href="https://www.benzinga.com/quote/EA/earnings">after-hours session</a>. According to analyst consensus estimates, EA is expected to report EPS of 43 cents on revenue of $1.286 billion.
During Electronic Arts&#8217; fourth-quarter earnings call in May, CEO Andrew Wilson announced that the development team for the upcoming Battlefield game is the largest in the franchise&#8217;s history, highlighting EA&#8217;s significant investment in its development. EA&#8217;s Motive, known for Star Wars: Squadrons and the Dead Space Remake, is working on Battlefield in addition to their current project, an Iron Man game.
Additionally, over the past three months, 16 analysts have evaluated Electronic Arts with a variety of opinions, both positive and negative. Their latest assessments highlight changes in sentiment over the past 30 days compared to previous months&#8230;<a href="https://www.benzinga.com/insights/analyst-ratings/24/07/40017884/beyond-the-numbers-16-analysts-discuss-electronic-arts-stock">Read More</a>
Read Also: <a href="https://www.benzinga.com/general/gaming/24/07/40035765/sag-aftra-calls-video-game-strike-over-ai-concerns">SAG-AFTRA Calls Video Game Strike Over AI Concerns</a>
<h2 class="wp-block-heading">Is EA A Good Stock To Buy?</h2>
When deciding whether to buy a stock, there are some key fundamentals investors may want to consider. One of these factors is revenue growth. Buying a stock is essentially a bet that the business will continue to grow and generate profits in the future.
Other important metrics to look at include a company's profitability, balance sheet, performance relative to a benchmark index and valuation compared to peers. For in-depth analysis tools and important financial data, check out <a href="https://pro.benzinga.com">Benzinga PRO</a>.
EA has a 52-week high of $150.48 and a 52-week low of $117.47.

Electronic Arts (EA) Stock Hits A New 52-Week High: What's Going On?

Contracts

European Aeronautic Defence And Space Unsponsored

EADSY

Leonardo CEO Says Back To "Rate 10" For Boeing Fuselages By 2025; In Talks With Airbus To Expand Collaboration For Rear Fuselage Of A220; Co In Negotiations With Boeing Over Slowdown Of 787 Production, Sees Positive Prospects For B787 In Long-term

WIIM

TERN

Terns Pharmaceuticals shares are trading lower after the company announced the departure of CFO Mark Vignola.

BMO Capital analyst Brian Pitz reiterates Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Outperform and maintains $56 price target.

RBLX

BMO Capital Reiterates Outperform on Roblox, Maintains $56 Price Target

<a href="https://www.businessinsider.com/amazon-healthcare-one-medical-billion-loss-cost-cutting-profitability-2024-7#:~:text=In%20December%2C%20Amazon%20projected%20more,profitability%20in%20its%20healthcare%20segment" title="https://www.businessinsider.com/amazon-healthcare-one-medical-billion-loss-cost-cutting-profitability-2024-7#:~:text=In%20December%2C%20Amazon%20projected%20more,profitability%20in%20its%20healthcare%20segment">https://www.businessinsider.com/amazon-healthcare-one-medical-billion-loss-cost-cutting-profitability-2024-7#:~:text=In%20December%2C%20Amazon%20projected%20more,profitability%20in%20its%20healthcare%20segment</a>.

Biotech

Guidance

General

AMZN

'Late Last Year, Amazon Projected Its Healthcare Businesses To Lose More Than $1B For 2024 - Business Insider Citing Internal Document

HSII

Heidrick & Struggles shares are trading higher after the company reported better-than-expected Q2 financial results. Also, the company issued Q3 net revenue guidance above estimates.

Wedbush analyst Daniel Ives maintains Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Outperform and raises the price target from $65 to $67.

VRNS

Wedbush Maintains Outperform on Varonis Systems, Raises Price Target to $67

TRNS

Transcat shares are trading lower after the company reported worse-than-expected Q1 revenue results.

Barrington Research analyst Vincent Colicchio maintains Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>) with a Outperform and maintains $68 price target.

CLMB

Barrington Research Maintains Outperform on Climb Global Solutions, Maintains $68 Price Target

CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares traded higher initially Tuesday morning but have since reversed following the company&#8217;s announcement that it entered into an exclusive license <a href="https://www.benzinga.com/news/24/07/40033170/cns-pharmaceuticals-expands-pipeline-with-in-license-of-late-stage-novel-potential-blood-brain-barri">agreement with Cortice Biosciences</a>.
The Details: CNS secured an exclusive license and the intellectual property rights for TPI 287, a potential treatment for glioblastoma multiforme (GBM).
CNS will pay Cortice 616, 698 shares of the company&#8217;s common stock in exchange for the license and intellectual property rights. In addition, there are possible future success-dependent milestone payments of cash or the company&#8217;s common stock&nbsp;
A multicenter Phase 1 study of TPI 287 combined with bevacizumab in recurrent GBM patients showed a progression-free survival (PFS) of 5.5 months and an overall survival (OS) of 13.4 months. In comparison, bevacizumab alone or with chemotherapy showed a PFS of 2-4 months and an OS of 6-9 months.
CNS believes that another one of its drug candidates for the treatment of GBM, Berubicin, could serve as an ideal complementary asset to TPI 287. 
John Climaco, CEO of CNS Pharmaceuticals, stated, &#8220;For years, our team has searched for another drug candidate with the same high level of human data-supported therapeutic potential in GBM as Berubicin. The in-licensing of TPI 287 is a transformational step forward and we are prepared for the next stage to execute our vision of CNS Pharmaceuticals being the leading biopharma company developing drugs for this devastating and currently inescapably fatal disease.&#8221;
The company intends to consult with the U.S. FDA to receive feedback on the design of a study aimed at registering TPI 287 for recurrent GBM, with plans to start the study in 2025. 
Related Link: <a href="https://www.benzinga.com/insights/analyst-ratings/24/07/40039420/expert-outlook-sage-therapeutics-through-the-eyes-of-14-analysts">Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts</a>
CNSP Price Action: At the time of publication, CNS shares are trading 60% lower at 41 cents, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Myriams-Fotos from Pixabay
.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Beroni Group Ltd Ordinary Shares

News

Latest news for Beroni Group Ltd Ordinary Shares (OTC:BNIGD) Stock